Mehran Ghasemzadeh: Assessing Antibody Burden and Platelet Exhaustion in Chronic ITP
Mehran Ghasemzadeh, Professor at High Institute for Research and Education in Transfusion Medicine, shared on LinkedIn about a recent article he and his colleagues co-authored, published in British Journal of Haematology, adding:
“New Publication | British Journal of Haematology
I’m pleased to share our group’s latest paper in chronic ITP, extending our prior work in Scientific Reports where we introduced a functional panel to assess platelet exhaustion and distinguish responder from non-responder patients.
Building on that foundation, and with sincere thanks to my great research team and special appreciation to my good friend Professor Elizabeth Gardiner, this study presents a modified, semi-quantitative immunofluorescence assay to assess total platelet-reactive antibody burden in chronic ITP.
Using this lab-designed approach, we show that higher antibody burden correlates with platelet functional exhaustion, greater bleeding severity, and poorer treatment response – outperforming platelet count as a clinical biomarker.
A defined signal threshold effectively discriminated responders from non-responders.”
Title: Design of a modified platelet immunofluorescence test to assess platelet-reactive antibody burden and its association with platelet functional exhaustion and clinical features in chronic immune thrombocytopenia
Authors: Ehteramolsadat Hosseini, Nazanin Heidari, Mohammad Faranoush, Seyed Mohammad Sadegh Pezeshki, Elizabeth E. Gardiner, Mehran Ghasemzadeh
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 24, 2026, 18:10Yazan Abou-Ismail: ClotCast Episode 8 – What Are Platelets?
-
Aug 24, 2026, 17:11Kristin Neves: Which Hematologic Parameters Guide Your PV Treatment Decisions?
-
Aug 24, 2026, 17:00Should Hormone Therapy Automatically Stop After a Thrombosis? – Thrombosis Canada
-
Aug 24, 2026, 16:52Davide Capodanno: 10 Trials to Watch at the ESC Hot Lines
-
Aug 24, 2026, 16:48Mohd Ashhad: The Science Behind a Safe Transfusion
-
Aug 24, 2026, 16:38PCSK9i Is a Powerful Lipid-Lowering Strategy – But Is It Also Anti-Inflammatory?- JACC Journals
-
Aug 24, 2026, 16:36Alejandro González Veliz։ Does ACC/AHA Lesion Complexity Still Matter?
-
Aug 24, 2026, 16:21Kamlesh Darji: Paraneoplastic Syndromes – Tumor with or without Mediator
-
Aug 24, 2026, 15:15Jim Hoffman: Could Targeting NETosis Reduce Long-Term Risk After STEMI?